利妥昔单抗治疗系统性硬化症相关间质性肺病:系统评价与荟萃分析
该系统评价与荟萃分析纳入20项研究(含2项随机对照试验,共575例)评估利妥昔单抗对SSc-ILD患者肺功能的影响。结果显示利妥昔单抗治疗6个月和12个月时FVC与DLCO均较基线显著改善,且感染风险低于对照组。
要点
- 利妥昔单抗治疗SSc-ILD在6个月和12个月时FVC与DLCO较基线显著改善。
- 与其它免疫抑制剂相比,利妥昔单抗组6个月FVC改善更优,12个月时FVC和DLCO相似。
- 利妥昔单抗组感染风险低于对照组。
核心结论
- 利妥昔单抗治疗SSc-ILD与第一年内FVC和DLCO的显著改善相关。
- 利妥昔单抗使用与较低的感染性不良事件相关。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed和Embase,纳入20项研究(2项随机对照试验、6项前瞻性研究、5项回顾性研究、7项会议摘要),共575例。
主要发现
- 利妥昔单抗使FVC较基线改善:6个月为4.49%(95%CI 0.25, 8.73),12个月为7.03%(95%CI 4.37, 9.7)。
- 利妥昔单抗使DLCO较基线改善:6个月为3.47%(95%CI 0.99, 5.96),12个月为4.08%(95%CI 1.51, 6.65)。
- 在两项与其它免疫抑制剂比较的研究中,利妥昔单抗组6个月FVC改善比对照组多1.03%(95%CI 0.11, 1.94)。
- 12个月随访时,利妥昔单抗组与对照组在FVC和DLCO方面相似。
- 利妥昔单抗组发生感染的风险低于对照组[OR 0.256(95%CI 0.104, 0.626),I2=0%,P=0.47]。
临床怎么用
- 对于SSc-ILD患者,利妥昔单抗可考虑作为改善肺功能的治疗选择,尤其在第一年内。
- 利妥昔单抗治疗时感染性不良事件风险较低,但需结合患者个体情况评估。
局限性
- 纳入研究包含会议摘要,证据质量可能受限。
- 仅两项研究比较了利妥昔单抗与其它免疫抑制剂,比较性结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the effect of rituximab (RTX) on the lung function parameters in SSc interstitial lung disease (SSc-ILD) patients. METHODS: PubMed and Embase were searched to identify studies on SSc-ILD treated with RTX, confined to a predefined inclusion and exclusion criteria. A systematic review and meta-analysis were performed on the included studies on changes in forced vital capacity (FVC) and diffusion capacity of carbon monoxide (DLCO) from baseline to 6 and 12 months of follow-up. RESULTS: A total of 20 studies (2 randomized controlled trials, 6 prospective studies, 5 retrospective studies and 7 conference abstracts) were included (n = 575). RTX improved FVC from baseline by 4.49% (95% CI 0.25, 8.73) at 6 months and by 7.03% (95% CI 4.37, 9.7) at 12 months. Similarly, RTX improved DLCO by 3.47% (95% CI 0.99, 5.96) at 6 months and 4.08% (95% CI 1.51, 6.65) at 12 months. In the two studies comparing RTX with other immunosuppressants, improvement of FVC by 6 months in the RTX group was 1.03% (95% CI 0.11, 1.94) greater than controls. At the 12 month follow-up, RTX treatment was similar to controls in terms of both FVC and DLCO. Patients treated with RTX had a lower chance of developing infections compared with controls [odds ratio 0.256 (95% CI 0.104, 0.626), I2 = 0%, P = 0.47). CONCLUSIONS: Treatment with RTX in SSc-ILD was associated with a significant improvement of both FVC and DLCO during the first year of treatment. RTX use was associated with lower infectious adverse events.
引用
- Goswami RP, Ray A, Chatterjee M, et al. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford). 2021. PMID: 33164098. doi:10.1093/rheumatology/keaa550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。